Sharda Cropchem Limited — PPTs, 14-05-2025: Investor Presentation

1. Financial Highlights:

Sharda Cropchem’s revenue rose 39% YoY in Q4 FY25 to Rs. 1,829 Cr and 37% YoY in FY25 to Rs. 4,320 Cr, driven by strong volume growth in Europe, NAFTA, and LATAM. Agrochemical segment revenue jumped 43% YoY to Rs. 3,773 Cr, led by herbicides (53% of segment revenue) and insecticides/fungicides. Gross margin improved 400bps to 29.9%, aided by price increases and operational efficiencies. EBITDA more than doubled to Rs. 682 Cr (15.8% margin), while PAT surged to Rs. 304 Cr from Rs. 32 Cr previously. The balance sheet remains solid with equity of Rs. 2,501 Cr, cash/liquid investments of Rs. 558 Cr, and working capital days reduced by 40 to 118 days.

2. Strategic Initiatives & Growth Drivers:

The company is expanding its factory-to-farmer distribution and sales presence across key regions. It aggressively invests in patent registrations, with 2,964 completed and 1,014 in process globally. The asset-light approach focuses on generics identification and dossier registrations rather than heavy manufacturing, supporting capital-efficient growth. FY25 capex was Rs. 420 Cr plus registration expenses. Margin improvement and operational efficiency remain key priorities.

3. Business Developments:

Sharda Cropchem benefits from diversified sourcing and partnerships with multiple manufacturers, enabling competitive pricing and a broad product portfolio. Its distributor network includes over 525 partners complemented by 500+ direct sales staff, reaching 80+ countries. Ongoing dossier filings position it well to capture opportunities from molecules going off patent.

4. Market Position & Competitive Advantage:

The company holds a strong position in the global generic crop protection market with a large IP/dossier portfolio serving advanced markets. The flexible, asset-light model allows agility and cost advantages. Broad geographic reach and an integrated distribution network enhance its scale. The factory-to-farmer strategy bolsters its goal to be a one-stop crop care solutions provider globally.

5. Investor Implications:

Robust volume growth, margin expansion, EBITDA doubling, and a sharp PAT turnaround underscore strong growth potential. The focused registration pipeline and geographic diversification strengthen a durable competitive edge. Execution risks include sustaining dossier approvals and margin stability amid raw material cost changes. Sharda Cropchem’s scalable model and strong balance sheet support its multi-year growth outlook in the expanding global agrochemical sector.